MX340094B - Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento. - Google Patents
Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento.Info
- Publication number
- MX340094B MX340094B MX2013004960A MX2013004960A MX340094B MX 340094 B MX340094 B MX 340094B MX 2013004960 A MX2013004960 A MX 2013004960A MX 2013004960 A MX2013004960 A MX 2013004960A MX 340094 B MX340094 B MX 340094B
- Authority
- MX
- Mexico
- Prior art keywords
- complement
- complement activation
- individual
- point
- lateral flow
- Prior art date
Links
- 230000024203 complement activation Effects 0.000 title abstract 5
- 230000000295 complement effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000003018 immunoassay Methods 0.000 title abstract 2
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/125—Adult respiratory distress syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40929710P | 2010-11-02 | 2010-11-02 | |
| PCT/US2011/058945 WO2012071145A1 (en) | 2010-11-02 | 2011-11-02 | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013004960A MX2013004960A (es) | 2013-12-16 |
| MX340094B true MX340094B (es) | 2016-06-27 |
Family
ID=46146161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013004960A MX340094B (es) | 2010-11-02 | 2011-11-02 | Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9182396B2 (https=) |
| EP (2) | EP3095876A1 (https=) |
| JP (1) | JP5859557B2 (https=) |
| AU (2) | AU2011332241B2 (https=) |
| CA (1) | CA2816423A1 (https=) |
| ES (1) | ES2564290T3 (https=) |
| MX (1) | MX340094B (https=) |
| WO (1) | WO2012071145A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8865164B2 (en) * | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
| AU2011332241B2 (en) * | 2010-11-02 | 2015-11-26 | Kypha, Inc. | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
| WO2014005138A1 (en) * | 2012-06-29 | 2014-01-03 | Kerschensteiner Daniel A | Colorimetric gelatinase assay |
| ES2695000T3 (es) * | 2013-06-10 | 2018-12-28 | Asahi Kasei Kabushiki Kaisha | Kit de diagnóstico inmunocromatográfico |
| WO2015168615A2 (en) * | 2014-05-02 | 2015-11-05 | Uab Research Foundation | Methods and compositions for diagnosis and treatment of meningitis |
| WO2017040243A1 (en) * | 2015-08-28 | 2017-03-09 | Kypha, Inc. | Methods for predicting flare and improving treatment of patients |
| KR102141591B1 (ko) * | 2016-05-13 | 2020-09-14 | 광주과학기술원 | 진단용 키트 |
| WO2019190877A1 (en) * | 2018-03-26 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | High throughput method for measuring the protease activity of complement c3 convertase |
| EP3581934A1 (en) * | 2018-06-14 | 2019-12-18 | Otto-von-Guericke-Universität Magdeburg | Complement factors for diagnosis of low-grade infections in a human subject |
| WO2021222169A1 (en) * | 2020-04-27 | 2021-11-04 | Zinselmeyer Bernd H | Methods and systems for lateral flow immunoassay of various biological materials including sars-cov2 |
| CA3170448A1 (en) * | 2020-09-28 | 2022-03-31 | Joseph M. Ahearn | Methods for determining a level of a cell fragment-bound complement activation product |
| CN116806312A (zh) * | 2021-01-26 | 2023-09-26 | 积水医疗株式会社 | 免疫学测定方法 |
| JP2024519582A (ja) * | 2021-05-07 | 2024-05-17 | カイファ， インコーポレイテッド | 標的測定 |
| WO2023192436A1 (en) * | 2022-03-31 | 2023-10-05 | Alexion Pharmaceuticals, Inc. | Singleplex or multiplexed assay for complement markers in fresh biological samples |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212071A (en) * | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
| JPS595958B2 (ja) | 1975-12-30 | 1984-02-08 | トウキヨウケイソウ カブシキガイシヤ | 変量測定・伝送装置 |
| DE3366421D1 (en) * | 1982-06-14 | 1986-10-30 | Upjohn Co | Method and kit for removing and assaying complement system fragments |
| SE452065B (sv) | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| SE452067B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Reagens for och sett vid immunkemisk bestemning av c3a |
| IL89790A (en) * | 1988-04-01 | 2002-05-23 | Johns Hopking University | Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification |
| WO2003062824A1 (en) * | 2002-01-23 | 2003-07-31 | Boditech Inc. | Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor |
| WO2004093636A2 (en) * | 2003-04-17 | 2004-11-04 | Rauno Joks | PLASMA C5a LEVELS AS AN INDICATOR OF ASTHMA SEVERITY |
| ES2342291T3 (es) | 2003-06-13 | 2010-07-05 | University Of Pittsburgh | Control de enfermedades inmunologicas, hematologicas e inflamatorias. |
| DK1687636T3 (da) * | 2003-09-29 | 2009-05-11 | Peas Inst Ab | Hurtig bestemmelse af forskellige former for hepatocytvækstfaktor (HGF) i legemsvæsker |
| WO2005078442A1 (en) | 2004-02-10 | 2005-08-25 | Dantini Daniel C | Comprehensive food allergy test |
| US20060292700A1 (en) * | 2005-06-22 | 2006-12-28 | Naishu Wang | Diffused interrupted lateral flow immunoassay device and method |
| WO2006124888A2 (en) * | 2005-05-16 | 2006-11-23 | Brendan Bioscience, Llc | Detection of antigen specific immunocomplexes |
| US7910381B2 (en) | 2005-10-13 | 2011-03-22 | BioAssay Works | Immuno gold lateral flow assay |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| EP2313527A4 (en) * | 2008-07-15 | 2012-11-21 | Rapid Pathogen Screening Inc | Lateral flow NUCLEIC DETECTOR |
| US20110251099A1 (en) * | 2008-12-30 | 2011-10-13 | Sudha Visvanathan | SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS |
| WO2010135717A2 (en) | 2009-05-21 | 2010-11-25 | Potentia Pharmaceuticals, Inc. | Complement assays and uses thereof |
| US8865164B2 (en) | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
| AU2011332241B2 (en) | 2010-11-02 | 2015-11-26 | Kypha, Inc. | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
-
2011
- 2011-11-02 AU AU2011332241A patent/AU2011332241B2/en active Active
- 2011-11-02 MX MX2013004960A patent/MX340094B/es active IP Right Grant
- 2011-11-02 ES ES11842681.6T patent/ES2564290T3/es active Active
- 2011-11-02 WO PCT/US2011/058945 patent/WO2012071145A1/en not_active Ceased
- 2011-11-02 JP JP2013537784A patent/JP5859557B2/ja active Active
- 2011-11-02 EP EP15199549.5A patent/EP3095876A1/en not_active Withdrawn
- 2011-11-02 CA CA2816423A patent/CA2816423A1/en not_active Abandoned
- 2011-11-02 US US13/287,432 patent/US9182396B2/en active Active
- 2011-11-02 EP EP11842681.6A patent/EP2635702B1/en active Active
-
2015
- 2015-08-13 US US14/825,437 patent/US9939446B2/en active Active
-
2016
- 2016-02-05 AU AU2016200772A patent/AU2016200772B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2635702A4 (en) | 2014-04-02 |
| US20150346211A1 (en) | 2015-12-03 |
| AU2016200772A1 (en) | 2016-02-25 |
| US20120141457A1 (en) | 2012-06-07 |
| AU2016200772B2 (en) | 2018-02-01 |
| ES2564290T3 (es) | 2016-03-21 |
| EP3095876A1 (en) | 2016-11-23 |
| US9182396B2 (en) | 2015-11-10 |
| AU2011332241B2 (en) | 2015-11-26 |
| MX2013004960A (es) | 2013-12-16 |
| EP2635702A1 (en) | 2013-09-11 |
| EP2635702B1 (en) | 2016-02-03 |
| CA2816423A1 (en) | 2012-05-31 |
| JP5859557B2 (ja) | 2016-02-10 |
| JP2014502347A (ja) | 2014-01-30 |
| AU2011332241A2 (en) | 2013-06-13 |
| WO2012071145A1 (en) | 2012-05-31 |
| US9939446B2 (en) | 2018-04-10 |
| AU2011332241A1 (en) | 2013-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX340094B (es) | Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento. | |
| Dumbser et al. | High order space–time adaptive ADER-WENO finite volume schemes for non-conservative hyperbolic systems | |
| HK1220279A1 (zh) | 预测对精神疾病治疗的应答的方法和系统 | |
| MX2016006252A (es) | Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono. | |
| GB2504022A (en) | Surface preparation | |
| WO2015102726A3 (en) | A microfluidic device for real-time clinical monitoring and quantitative assessment of whole blood coagulation | |
| MX355416B (es) | Biomarcadores de cancer de pulmon y usos de los mismos. | |
| CL2013003433A1 (es) | Método para analizar una muestra biológica de un sujeto con cáncer que comprende determinar un nivel de expresión de los biomarcadores gli-1, otx-2, shroom2, pdlim3, y sphk1 en dicha muestra, en donde el nivel de expresión de los biomarcadores en coparación con un control, proporciona un indicador de diagnóstico de si el sujeto tiene una probabilidad aumentada de respuesta a: un ácido metil-4’-trifluorometoxi-bifenil-3-carboxílixo [6-(cis-2,6-dimetil-morfolino-4-il)-piridin-3-il]-amida, ó 2-[(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2’] bipirizanil-5’-il]-propan-2-ol; método para seleccionar a un sujeto que tiene cáncer para el tratamiento con uno de dichos compuestos, el cual comprende determinar el nivel de expresión de shroom2 o sphk1, en una muestra biológica del sujeto. | |
| GB2484631A (en) | System and methods for monitoring a well | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| HK1208256A1 (en) | Microfluidic pump | |
| IN2014KN02809A (https=) | ||
| GB2544922A (en) | Methods and systems for simulating a hydrocarbon field using a multi-point well connection method | |
| GB201113992D0 (en) | Device | |
| GB2538374A (en) | Determining formation gas composition during well drilling | |
| WO2014141293A3 (en) | A method and system for estimation of blood anylates | |
| EA201791707A1 (ru) | Переносное устройство для оперативного измерения концентрации сероводорода в выходящем газовом потоке | |
| WO2014072832A3 (en) | Biomarkers for cervical cancer | |
| WO2014126796A3 (en) | Methods of diagnosing, treating and monitoring diabetic retinopathy | |
| EP4328324A3 (en) | Methods of diagnosing epilepsy | |
| MX2018016216A (es) | Deteccion de analitos de flujo lateral. | |
| WO2014145797A3 (en) | Method for treating eclampsia and preeclampsia | |
| WO2013088140A3 (en) | Tenascin-c and use thereof in rheumatoid arthritis | |
| FR2991771B1 (fr) | Dispositif de controle de la coagulation d'un fluide, notamment du lait, et procede de controle associe | |
| WO2014009055A9 (en) | Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |